Literature DB >> 7509790

Common tetrasaccharide epitope NeuAc alpha 2-->3Gal beta 1-->3(Neu-Ac alpha 2-->6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities.

S Saito1, S B Levery, M E Salyan, R I Goldberg, S Hakomori.   

Abstract

A novel globo-series disialoganglioside, disialosyl galactosyl globoside (Structure 1 below), defined by new monoclonal antibody (mAb) RM2, was isolated and characterized as having terminal structure identical to that of ganglio-series ganglioside GD1 alpha (Structure 2) and a common mucin-type epitope (Structure 3) widely distributed in glycoproteins such as glycophorin A. While these three structures share a common nonreducing tetrasaccharide terminus, mAb RM2 showed strong specific reactivity only with Structure 1, not with Structures 2 or 3. Another mAb, QSH2, reacted strongly with Structure 3 but did not cross-react with Structures 1 or 2. Conformational molecular models based on minimum energy hard sphere exoanomeric calculations suggest that Structure 1 presents a unique surface topology distinct from that of Structures 2 or 3. Our findings suggest the novel concept that reactivity of a common carbohydrate epitope with different antibodies or ligands is highly dependent on the type of carrier glycosylceramide or carrier O-linked peptide. [formula: see text]

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509790

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  The glycosynapse.

Authors:  Sen-itiroh Hakomori Si
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 2.  Selectin ligands.

Authors:  A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

3.  Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.

Authors:  Severine Van Slambrouck; Wim F A Steelant
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

4.  Selectin ligands on human melanoma cells.

Authors:  N Miller; R G Vile; I R Hart
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

5.  Prominent immunogenicity of monosialosyl galactosylgloboside, carrying a stage-specific embryonic antigen-4 (SSEA-4) epitope in the ACHN human renal tubular cell line-a simple method for producing monoclonal antibodies against detergent-insoluble microdomains/raft.

Authors:  Y U Katagiri; K Ohmi; C Katagiri; T Sekino; H Nakajima; T Ebata; N Kiyokawa; J Fujimoto
Journal:  Glycoconj J       Date:  2001-04       Impact factor: 2.916

Review 6.  Traveling for the glycosphingolipid path.

Authors:  S Hakomori
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

7.  Chemoenzymatic synthesis of the oligosaccharide moiety of the tumor-associated antigen disialosyl globopentaosylceramide.

Authors:  Ingrid M E 't Hart; Tiehai Li; Margreet A Wolfert; Shuo Wang; Kelley W Moremen; Geert-Jan Boons
Journal:  Org Biomol Chem       Date:  2019-08-07       Impact factor: 3.876

8.  Clinicopathological significance of ganglioside DSGb5 expression in renal cell carcinoma.

Authors:  Jun Itoh; Akihiro Ito; Shuichi Shimada; Yoshihide Kawasaki; Narihiko Kakoi; Hideo Saito; Koji Mitsuzuka; Mika Watanabe; Makoto Satoh; Seiichi Saito; Yoichi Arai
Journal:  Glycoconj J       Date:  2017-02-15       Impact factor: 2.916

Review 9.  Structure and function of glycosphingolipids and sphingolipids: recollections and future trends.

Authors:  Sen-itiroh Hakomori
Journal:  Biochim Biophys Acta       Date:  2007-09-06

10.  Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues.

Authors:  A Ito; S Saito; T Masuko; M Oh-Eda; T Matsuura; M Satoh; F M Nejad; T Enomoto; S Orikasa; S I Hakomori
Journal:  Glycoconj J       Date:  2001-06       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.